Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513722 | 1.00 | CTSD (0.32) | CTSDBACE1KLK5CA1CA2 | |
| SCHEMBL7526880 | 1.00 | CTSD (0.32) | CTSDBACE1KLK5CA1CA2 | |
| SCHEMBL7526876 | 1.00 | CTSD (0.32) | CTSDBACE1KLK5CA1CA2 | |
| SCHEMBL7552350 | 0.82 | SYK (0.32) | CTSDBACE1KLK5KLK7GAA | |
| SCHEMBL7451863 | 0.82 | SYK (0.32) | CTSDBACE1KLK5KLK7GAA | |
| SCHEMBL7558417 | 0.82 | SYK (0.32) | CTSDBACE1KLK5KLK7GAA | |
| SCHEMBL7513733 | 0.80 | CTSK (0.45) | CTSDBACE1KLK5KLK7CTSK | |
| SCHEMBL7447808 | 0.68 | — | — | |
| SCHEMBL23833195 | 0.68 | CA1 (0.46) | CA1CA2CA7GAACTSK | |
| SCHEMBL15994357 | 0.68 | CA1 (0.46) | CA1CA2CA7GAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165222-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-07 | — | — | US | claimed |
| US-20020165222-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165222-A1 | Protease inhibitors | CTSK, CTSZ, CTSE | CTSD 6/4885BACE1 118/4885KLK5 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.